Why Is Inflammatory Focused Matinas BioPharma Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Matinas BioPharma Holdings Inc (NASDAQ:MTNB) reported positive results from in vivo studies for oral delivery of LNC-formulated oligonucleotides targeting inflammatory cytokines TNFα and IL-17A. These studies showed successful results in animal models for acute inflammatory diseases. Earlier, Matinas confirmed the in vitro potency of these oligonucleotides. The studies demonstrated significant reductions in cytokine levels and clinical disease activity scores in models of acute colitis and psoriasis. Following the news, MTNB shares surged by 21.41% to $0.2450.
December 27, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Matinas BioPharma's stock price increased by 21.41% following the announcement of positive in vivo study results for its LNC-formulated oligonucleotides targeting inflammatory cytokines.
The positive study results are likely to increase investor confidence in Matinas BioPharma's pipeline, potentially leading to increased investment and a higher stock price in the short term. The significant surge in stock price reflects the market's positive reception to the news.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100